Best Practices for Preventing Thrombosis in Parenteral Nutrition Patients

August 21, 2025

Parenteral nutrition (PN) is an essential medical intervention for patients who are unable to absorb nutrients through their gastrointestinal tract. Despite its life-saving benefits, PN carries significant risks, notably thrombosis linked to central venous catheter use. This article delves into evidence-based practices and expert recommendations to prevent thrombosis in parenteral nutrition patients, focusing on catheter management, pharmacological interventions, risk factors, and management strategies.

Catheter Management and Insertion Techniques

Appropriate catheter selection and insertion site

Choosing the right catheter is critical in minimizing the risk of catheter-related thrombosis (CRT) for patients receiving parenteral nutrition. Peripherally Inserted Central Catheters (PICCs) and central venous catheters (CVCs) vary in their potential for causing thrombosis. Best practices suggest that thoracic ports are preferred over femoral ports due to their lower risk of complications, including CRT. Opting for the smallest catheter caliber that meets the clinical needs also has a positive impact on reducing thrombosis risk.

Vein selection must involve careful consideration. The internal jugular vein is typically optimal for catheter insertion, as it offers a direct route to the superior vena cava while avoiding areas with a history of clot formation. Proper positioning of the catheter tip is vital, ideally near the atrio-caval junction to further reduce CRT incidence.

Proper catheter stabilization

Stabilizing the catheter at the site of emergence is essential for reducing movement that could lead to thrombus formation. Secure dressing techniques and regular assessments of the insertion site can help prevent complications. Training healthcare providers on catheter maintenance and follow-up care further reinforces these efforts. The use of chlorhexidine-impregnated dressings has been shown to lower the risk of catheter-related bloodstream infections, thereby indirectly helping to prevent thrombotic episodes.

Role of catheter size in preventing thrombosis

Catheter size significantly influences the risk of thrombosis, as larger-bore catheters occupy more space in the vein, potentially disrupting blood flow. It's recommended that catheters be less than 33% of the internal vein diameter to minimize this risk. Continuous monitoring and evaluation of catheter function and integrity are vital, alongside education for patients regarding the signs of thrombosis to facilitate early detection and intervention.

How can PICC line-related thrombosis be prevented in patients receiving parenteral nutrition?

To prevent PICC line-related thrombosis in patients receiving parenteral nutrition, it is essential to select appropriate catheter materials, such as silicone or polyurethane, which are associated with lower thrombosis rates. Proper and careful vein selection during insertion, avoiding areas with a history of thrombosis, can further reduce risk. Healthcare providers should also ensure optimal insertion techniques and minimize the invasiveness of the procedure. Regular monitoring for signs and symptoms of thrombosis, including pain, redness, and swelling, is crucial for early detection and timely intervention. Additionally, employing a multidisciplinary vascular access team can enhance management and adherence to best practices, thus improving patient safety.

Pharmacological Interventions for Thrombosis Prevention

What pharmacological interventions are used to prevent thrombosis in patients receiving parenteral nutrition?

Pharmacological interventions to prevent thrombosis in patients receiving parenteral nutrition primarily focus on the use of low molecular weight heparin (LMWH) and other anticoagulants.

  • Low Molecular Weight Heparin (LMWH) : This has emerged as a leading choice due to its ease of use and effectiveness in certain patient populations. Evidence suggests that while LMWH shows little to no significant difference in severe cases like pulmonary embolism or symptomatic deep vein thrombosis (DVT) compared to no prophylactic treatment, it can reduce the incidence of asymptomatic DVT, albeit with very low certainty.

  • Other Anticoagulants : Drugs such as fondaparinux have also been considered. Additionally, while oral anticoagulants including rivaroxaban and apixaban displayed minimal effects on symptomatic DVTs, studies reported no cases of pulmonary embolism with rivaroxaban, underscoring its relative safety.

  • Aspirin : This common medication has shown no thromboembolic events in patients when compared against those not receiving prophylaxis, indicating a potential role in some patients.

What factors influence the choice of prophylaxis in individual patients?

The selection of anticoagulant therapy should always consider patient-specific risk factors such as history of thrombosis and underlying conditions. For instance, those with previous DVT or hypercoagulable states might require more intensive prophylactic measures.

How does interprofessional collaboration enhance thrombosis prevention?

Interprofessional collaboration is vital for implementing effective DVT prophylaxis strategies. It involves coordinated efforts among dietitians, pharmacists, and nursing staff to monitor patient conditions closely, adjust therapies as needed, and educate patients about their risks and the importance of adhering to prophylactic treatments. This comprehensive approach enables tailored patient care, ultimately enhancing outcomes and reducing thrombosis-related complications.

General Strategies to Prevent Thrombosis

What general strategies can help reduce the risk of thrombosis in patients on parenteral nutrition?

To reduce the risk of thrombosis in patients on parenteral nutrition, it is essential to implement several key strategies. Staying active and incorporating leg movements, such as ankle and foot exercises, can help improve circulation.

Hydration is also crucial; ensuring that patients drink plenty of fluids unless otherwise advised helps maintain optimal blood viscosity. Dehydration can increase the risk of clot formation, making adequate fluid intake a priority in care regimens.

Awareness of the symptoms of deep vein thrombosis (DVT) and pulmonary embolism (PE) is vital for timely medical intervention. Patients should be educated on signs such as swelling, pain, or discoloration in the limbs, as well as difficulty breathing or chest pain, which could suggest a PE. Recognizing these symptoms allows for prompt evaluation and treatment, significantly improving outcomes.

Additionally, healthcare providers may prescribe anticoagulant medications for at-risk patients. This is especially important for those with a history of thrombosis or who are more susceptible due to factors like extended immobility or certain medical conditions. Continuous monitoring and support from specialized clinics are essential for optimal management and prevention of thromboembolic events.

Understanding Risk Factors and Symptoms

Identifying Risk Factors for CRT and CVT

Catheter-related thrombosis (CRT) and central venous thrombosis (CVT) pose serious risks for patients undergoing long-term parenteral nutrition (PN). Understanding the risk factors is crucial for effective management. The most significant risk factor for developing CRT is the presence of a central venous catheter, especially when inserted via the femoral vein, which has shown higher rates of infection. Other contributing factors include:

  • Patient-related Factors : Conditions like malignancy, hypercoagulable states, and a personal history of thrombosis significantly increase risk.
  • Technical Factors : The type of catheter used, catheter size, and the insertion technique matter. Smaller caliber catheters and proper placement at the atrio-caval junction are preferable to minimize thrombotic risk.
  • Medication Factors : While anticoagulation therapy such as low molecular weight heparin (LMWH) can be beneficial, it is not routinely recommended for all patients unless they exhibit high thrombotic risk.

Clinical Symptoms Indicative of Thrombosis

Patients with CRT or CVT may exhibit specific clinical symptoms that necessitate prompt evaluation. Common symptoms include:

  • Swelling : Unexpected swelling in the extremities due to impaired blood flow.
  • Pain : Localized pain at the catheter insertion site or in the affected limb.
  • Redness : Visible redness or discoloration at the site or in surrounding tissues.
  • Fever : A mild to moderate fever may indicate inflammation or infection associated with thrombosis.

Impact on Patient Care

The implications of CRT and CVT extend beyond immediate symptoms. Thrombosis can lead to loss of venous access, complicating therapy for patients reliant on PN. In severe cases, it may necessitate surgical interventions or even reduce the feasibility of transplantation options when vascular compromise is significant. Monitoring for risk factors and symptoms is essential in the multidisciplinary care of patients receiving parenteral nutrition, including regular assessments of vascular health, ensuring appropriate catheter management, and considering prophylactic strategies on a case-by-case basis.

Central Venous Access: Technique and Safety

Preferable Sites for Catheter Insertion

When it comes to central venous access, the selection of the insertion site is crucial. The jugular vein is generally preferred, with over 60% of centers opting for this site due to its accessibility and the reduced risk of complications. Insertion via the femoral vein is discouraged because it is associated with a higher risk of infection.

Use of Ultrasound Guidance

Utilizing ultrasound guidance during catheter insertion is highly recommended. This approach has shown to significantly increase the success rate of the procedure and reduce complications. Hospitals often adhere to strict protocols, employing real-time imaging techniques to ensure accurate placement of the catheter.

Techniques for Proper Catheter Tip Positioning

Proper positioning of the catheter tip is essential for minimizing the risk of catheter-related thrombosis (CRT). The ideal location of the catheter tip is at or near the atrio-caval junction of the superior vena cava (SVC). This positioning helps in promoting optimal blood flow while keeping complications at bay. Regular assessment and monitoring of catheter position during and after insertion are also recommended to ensure proper placement.

Central Venous Access Best Practices Description Importance
Insertion Site Preferring jugular over femoral Reduces infection risk
Ultrasound Guidance Utilization during insertion Improves success rate
Catheter Tip Positioning At or near atrio-caval junction Minimizes CRT risks

Management of Catheter-Related Thrombosis

Diagnosis and treatment of CRT

Catheter-related thrombosis (CRT) poses significant risks for patients requiring long-term parenteral nutrition. Diagnosis typically involves imaging techniques like Doppler ultrasound or CT venogram, which help confirm central venous thrombosis (CVT). These diagnostic methods are crucial, particularly since timely management can avert complications such as the loss of venous access.

Role of thrombolysis and anticoagulation

For acute cases of CVT, immediate intervention is essential. Catheter-directed thrombolysis, performed by specialists, may be indicated, especially within 14 days of symptoms onset. If a thrombus is found, clinicians usually recommend systemic anticoagulation for at least three months after catheter removal, or continuing minimum thromboprophylaxis if the catheter remains in situ.

Monitoring and long-term management strategies

Long-term management of patients on parenteral nutrition should include regular monitoring of catheter sites for complications, such as signs of infection or recurrent thrombotic events. Education and careful training for healthcare providers regarding catheter insertion techniques and maintenance protocols are paramount to optimizing patient outcomes. Implementing a multidisciplinary approach involving dietitians, pharmacists, and nurses will further enhance the management of CRT and the overall care of parenteral nutrition patients.

The Role of Education and Training

Importance of Training Healthcare Personnel

Education and training of healthcare personnel play a crucial role in the prevention of catheter-related thrombosis (CRT) and a range of complications associated with long-term parenteral nutrition (PN). Properly trained staff can ensure that central venous catheters (CVCs) are inserted and maintained in accordance with best practices, significantly lowering the risk of thrombosis and infections.

Protocols for Catheter Care and Infection Prevention

Developing and adhering to established protocols for catheter care is imperative. Key protocols include the use of maximal sterile barriers during insertion, daily assessments of catheter sites for infection, and employing antiseptic techniques such as chlorhexidine for skin preparation.

Impact on Thrombotic Risk Reduction

The impact of these training programs is evident when comparing outcomes in differing healthcare settings. Facilities with comprehensive training and protocols witness a notable decrease in thrombotic events. Moreover, systems that engage multidisciplinary teams—including nurses, pharmacists, and dietitians—are particularly effective in enhancing patient outcomes and minimizing complications associated with long-term PN.

Through ongoing education and adherence to guidelines, healthcare providers can significantly mitigate the risks of thromboembolic complications, thereby improving the safety of patients reliant on parenteral nutrition.

Importance of Interdisciplinary Approaches

Involvement of dietitians, pharmacists, and nurses

The management of patients on parenteral nutrition (PN) requires a collaborative approach involving various healthcare professionals. Dietitians play a crucial role in assessing nutrient needs and ensuring that the nutritional requirements are met adequately. Pharmacists contribute by managing medication regimens, including any necessary anticoagulation therapy to mitigate thrombotic risk.

Enhancing patient outcomes through teamwork

Teamwork among healthcare professionals leads to improved patient outcomes. Regular communication among dietitians, pharmacists, and nurses fosters a holistic understanding of each patient's unique needs. For instance, nurses can provide essential monitoring of micronutrient levels and infusion rates, while pharmacists help prevent drug interactions or complications from anticoagulation, allowing for optimal nutrition and minimal thrombotic events.

Addressing nutritional and thrombotic aspects collaboratively

Given the complexities of long-term PN and its associated risks, such as catheter-related thrombosis (CRT), an interdisciplinary approach ensures comprehensive care. Collaborative protocols can be established to monitor patients closely, address any nutritional deficiencies, and implement timely preventative measures against thrombosis. This strategy not only streamlines care but also promotes safety and effectiveness in managing patients on PN.

In summary, incorporating the expertise of various healthcare professionals significantly enhances the quality of care for patients requiring parenteral nutrition, effectively addressing both nutritional and thrombotic concerns.

Monitoring and Adjusting Nutritional Support

Assessment of fluid and electrolyte balance

Regular evaluation of fluid and electrolyte levels is essential for patients on parenteral nutrition (PN). Maintaining balance can help in preventing complications associated with long-term catheter use, particularly thrombosis. Regular blood tests ensure that deviations are caught early, allowing for timely interventions.

Micronutrient monitoring to minimize thrombosis risk

Monitoring micronutrient levels is critical to enhance overall patient health outcomes. Adequate delivery of vitamins and minerals prevents deficiencies that could escalate the risk of thrombosis. Keeping these levels within an optimal range contributes significantly to the body’s ability to function correctly and reduces associated risks with long-term PN.

Adjustments in PN to enhance patient safety

Tailoring PN formulations based on ongoing assessments can significantly reduce health complications. Adjustments may include altering macronutrient composition or fluid volumes based on individual patient needs. This proactive approach not only addresses nutritional requirements but also mitigates potential risks related to thromboembolic events.

Best Practices for Pediatric Patients

Safety measures in pediatric PN

Ensuring the safety of pediatric patients on home parenteral nutrition (HPN) is crucial. This includes implementing strict protocols for central venous catheter (CVC) care, which help minimize the risks of thrombotic events and infections. A significant number of centers have adopted taurolidine line locks to lower the rate of catheter-related bloodstream infections, though this practice varies among institutions.

Prophylactic anticoagulation in children

While routine anticoagulation is not commonly practiced for all pediatric patients on parenteral nutrition, it is recommended for those at heightened risk of thrombosis, particularly those dependent on long-term CVCs. Children with a history of catheter-associated thrombosis can particularly benefit from secondary prophylaxis to reduce recurrence rates.

Addressing increased thrombotic risks

To effectively manage the increased thrombotic risks associated with pediatric patients, healthcare providers should carefully select catheter types and insertion sites. Employing ultrasound guidance during catheter placement, along with training for staff in best insertion techniques, forms an integral part of prevention strategies in this vulnerable population. Regular assessments and a comprehensive care plan tailored to the child’s unique needs also play critical roles in reducing thromboembolic complications.

Innovations in PN and Thrombosis Prevention

Emerging Technologies and Approaches

In the realm of long-term parenteral nutrition (PN), innovative technologies are evolving to minimize risks associated with catheter-related thrombosis (CRT). Enhanced catheter designs featuring smaller diameters and improved materials have emerged, with studies suggesting that using smaller calibers can significantly reduce thrombosis rates. Additionally, the application of ultrasound guidance during catheter insertion has proven effective in enhancing placement success and minimizing complications.

Research Findings on Novel Strategies

Recent research underscores the importance of individualized patient assessments for thrombotic risk management. The adoption of daily low molecular weight heparin (LMWH) for high-risk patients has shown promise in reducing thrombus formation. A focus on modifiable risk factors—such as ensuring correct catheter positioning at the atrio-caval junction—has also highlighted effective strategies for prevention. Encouragingly, guidelines recommend employing maximum sterile barrier precautions during catheter insertion to mitigate infection risks, which directly correlate with thrombotic events.

Future Directions for Thrombosis Risk Reduction

Looking ahead, interdisciplinary approaches involving dietitians, pharmacists, and nurses play an essential role in refining thrombus prevention strategies in PN. Continuous feedback loops involving regular assessments of instruction adherence and protocol effectiveness are critical. Future research is likely to explore the integration of electronic monitoring technologies for catheter maintenance, allowing for prompt identification and resolution of complications. Overall, these evolving practices aim to enhance the safety and efficacy of long-term parenteral nutrition by comprehensively addressing thrombosis risks.

Concluding Thoughts on Thrombosis Prevention in Parenteral Nutrition

Mitigating the risk of thrombosis in parenteral nutrition patients requires a comprehensive approach that includes optimal catheter management, careful selection of pharmacological interventions, and timely application of multidisciplinary practices. By staying informed and adopting evidence-based recommendations, healthcare providers can significantly reduce thrombotic risks, ultimately enhancing patient outcomes and the overall success of parenteral nutrition therapy.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More